Last reviewed · How we verify
Incobotulinumtoxin A Injectable Product
Incobotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.
Incobotulinumtoxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | Incobotulinumtoxin A Injectable Product |
|---|---|
| Also known as | Xeomin |
| Sponsor | University of Utah |
| Drug class | Botulinum toxin |
| Target | SNAP-25 (synaptosome-associated protein of 25 kDa) |
| Modality | Small molecule |
| Therapeutic area | Neurology, Dermatology, Aesthetics |
| Phase | FDA-approved |
Mechanism of action
This botulinum toxin serotype A derivative irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release at the neuromuscular junction. This results in temporary flaccid paralysis of injected muscles. The effect is reversible over months as new neuromuscular junctions form.
Approved indications
- Cervical dystonia
- Blepharospasm
- Hemifacial spasm
- Glabellar lines (aesthetic)
- Crow's feet (aesthetic)
- Forehead lines (aesthetic)
Common side effects
- Headache
- Injection site pain or bruising
- Muscle weakness
- Eyelid ptosis
- Dry mouth
- Neck pain
Key clinical trials
- Prevention Atrial Fibrillation by BOTulinum Toxin Injections (BOTAF) (PHASE3)
- Incobotulinumtoxin A and Yoga-like Isometric Exercise in Adolescent Idiopathic Lumbar Scoliosis (PHASE2)
- Retrospective Evaluation of Combination Treatment With the Ulthera System
- Comparison of Three Botulinum Neuromodulators for Management of Facial Synkinesis (PHASE4)
- Investigation of Efficacy of incobotulinumtoxinA (Xeomin) in Relieving Symptoms of Restless Leg Syndrome. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Incobotulinumtoxin A Injectable Product CI brief — competitive landscape report
- Incobotulinumtoxin A Injectable Product updates RSS · CI watch RSS
- University of Utah portfolio CI